Halofuginone

Drug Profile

Halofuginone

Alternative Names: Halofuginone hydrobromide; HT-100; Stenorol™; Tempostatin™

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Collgard Biopharmaceuticals
  • Developer Akashi Therapeutics; Collgard Biopharmaceuticals
  • Class Antifibrotics; Piperidines; Quinazolinones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Collagen type I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scleroderma; Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Discontinued Bladder cancer; Cancer; Coronary artery restenosis; Hepatic fibrosis; Kidney disorders; Renal fibrosis; Scleroderma

Most Recent Events

  • 21 Apr 2017 Akashi Therapeutics terminates the HALO-DMD-03 phase II trial for Duchenne muscular dystrophy in USA (NCT02525302)
  • 21 Apr 2017 Akashi Therapeutics terminates the phase II HALO extension trial for Duchenne muscular dystrophy in USA as the dosing was stopped (PO) (NCT01978366)
  • 22 Mar 2017 Akashi Therapeutics plans the HALO-DMD-04 trial for Duchenne muscular dystrophy in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top